Genzymea Sanofi Company
Rabbit Anti thymocyte globulin(Genzyme, a Sanofi Company)은 AML, Childhood 표적 치료제로, Bone Marrow Failure; Osteopetrosis 영역에서 개발·상용화 중입니다. Phase 3 후기 임상 단계입니다. PFS: 24. 차별점: novel prolonged-release formulation of tacrolimus with enhanced bioavailability.
AML, Childhood
Bone Marrow Failure; Osteopetrosis
Active
novel prolonged-release formulation of tacrolimus with enhanced bioavailability
Cytokine Release Syndrome and Cardiogenic Shock Following Anti-Thymocyte Globulin Induction in a Kidney Transplant R
apoptosis of B cells in the systemic lymph nodes caused by the ATG administration
Biomarker of Rejection in Genetically Engineered Pig-to-Non-Human Primate Kidney Xenotransplantation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Genzymea Sanofi Company
Rabbit Anti thymocyte globulin(Genzyme, a Sanofi Company)은 AML, Childhood 표적 치료제로, Bone Marrow Failure; Osteopetrosis 영역에서 개발·상용화 중입니다. Phase 3 후기 임상 단계입니다. PFS: 24. 차별점: novel prolonged-release formulation of tacrolimus with enhanced bioavailability.
AML, Childhood
Bone Marrow Failure; Osteopetrosis
Active
novel prolonged-release formulation of tacrolimus with enhanced bioavailability
Cytokine Release Syndrome and Cardiogenic Shock Following Anti-Thymocyte Globulin Induction in a Kidney Transplant R
apoptosis of B cells in the systemic lymph nodes caused by the ATG administration
Biomarker of Rejection in Genetically Engineered Pig-to-Non-Human Primate Kidney Xenotransplantation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.